|
|
 Previous Article | Table of Contents | Next Article 
The effects of daily recombinant human granulocyte colony-stimulating
factor administration on normal granulocyte donors undergoing leukapheresis
[see comments]
WI Bensinger, TH Price, DC Dale, FR Appelbaum, R Clift, K Lilleby, B Williams, R Storb, ED Thomas and CD Buckner
Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
The effects of daily administration of recombinant human granulocyte
colony-stimulating factor (rhG-CSF) to eight normal volunteers donating
granulocytes for neutropenic relatives undergoing marrow transplantation
were studied. Granulocyte donors consisted of seven marrow donors (5
syngeneic, 2 HLA identical) and one haploidentical son who had not donated
marrow. All donors were administered daily rhG-CSF at a mean dose of 5
micrograms/kg/d (range 3.5 to 6.0) for a mean of 11.75 days (range 9 to 14
days), and granulocytes were collected a mean of 7.6 times (range 4 to 12).
RhG-CSF was well tolerated and only minor side effects were observed. All
donors became anemic from marrow donation and the removal of red blood
cells during the collection procedures. Red blood cell transfusions were
not given. All donors had a decrease in platelet counts and the magnitude
of the decrement appeared to be greater than in historical donors. This was
due in part to increased removal of platelets with the collection product,
but a direct effect of rhG-CSF on platelet production cannot be excluded.
The mean precollection granulocyte level was 29.6 x 10(9)/L (range 11.8 to
79.8), which was a 10-fold increase over baseline. The mean number of
granulocytes collected was 41.6 x 10(9) (range 1.3 to 144.1), which was a
six-fold increase over historical donors not receiving rhG-CSF. The mean
granulocyte level 24 hours after transfusion into neutropenic recipients
was 0.95 x 10(9)/L (median 0.57 and range .06 to 9.47). This study
indicates that rhG-CSF is safe to administer to normal individuals,
significantly improves the quantity of granulocytes collected, and results
in significant circulating levels of granulocytes in neutropenic
recipients. Further studies to evaluate rhG- CSF in normal granulocyte
donors are warranted.
Volume 81,
Issue 7,
pp. 1883-1888,
04/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. R Placzek, I-M. Chung, H. M Macedo, S. Ismail, T. Mortera Blanco, M. Lim, J. Min Cha, I. Fauzi, Y. Kang, D. C.L Yeo, et al.
Stem cell bioprocessing: fundamentals and principles
J R Soc Interface,
March 6, 2009;
6(32):
209 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Sasaki, R. Kuroda, K. Ishida, S. Kubo, T. Matsumoto, Y. Mifune, K. Kinoshita, K. Tei, T. Akisue, Y. Tabata, et al.
Enhancement of Tendon-Bone Osteointegration of Anterior Cruciate Ligament Graft Using Granulocyte Colony-Stimulating Factor
Am. J. Sports Med.,
August 1, 2008;
36(8):
1519 - 1527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. van Pel, H. Hagoort, M. J. Kwakkenbos, J. Hamann, and W. E. Fibbe
Differential role of CD97 in interleukin-8-induced and granulocyte-colony stimulating factor-induced hematopoietic stem and progenitor cell mobilization
Haematologica,
April 1, 2008;
93(4):
601 - 604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. H. Segal and T. J. Walsh
Current Approaches to Diagnosis and Treatment of Invasive Aspergillosis
Am. J. Respir. Crit. Care Med.,
April 1, 2006;
173(7):
707 - 717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. van Pel, R. van Os, G. A. Velders, H. Hagoort, P. M. H. Heegaard, I. J. D. Lindley, R. Willemze, and W. E. Fibbe
Serpina1 is a potent inhibitor of IL-8-induced hematopoietic stem cell mobilization
PNAS,
January 31, 2006;
103(5):
1469 - 1474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Engel, M. Scholz, and M. Loeffler
A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy
Blood,
October 15, 2004;
104(8):
2323 - 2331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Leger and T. J. Nevill
Hematopoietic stem cell transplantation: a primer for the primary care physician
Can. Med. Assoc. J.,
May 11, 2004;
170(10):
1569 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Lin, S. Adachi, K.-I. Watanabe, K. Umeda, and T. Nakahata
Serial Granulocyte Transfusions as a Treatment for Sepsis Due to Multidrug-Resistant Pseudomonas aeruginosa in a Neutropenic Patient
J. Clin. Microbiol.,
October 1, 2003;
41(10):
4892 - 4893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Vij, J. F. DiPersio, P. Venkatraman, K. Trinkaus, L. T. Goodnough, R. A. Brown, H. J. Khoury, S. M. Devine, A. Oza, S. Shenoy, et al.
Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation
Blood,
March 1, 2003;
101(5):
2067 - 2069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Velders, J. F. M. Pruijt, P. Verzaal, R. van Os, Y. van Kooyk, C. G. Figdor, E.-J. F. M. de Kruijf, R. Willemze, and W. E. Fibbe
Enhancement of G-CSF-induced stem cell mobilization by antibodies against the beta 2 integrins LFA-1 and Mac-1
Blood,
June 17, 2002;
100(1):
327 - 333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yamada, K. Suzuki, S. Kudo, M. Totsuka, S. Nakaji, and K. Sugawara
Raised plasma G-CSF and IL-6 after exercise may play a role in neutrophil mobilization into the circulation
J Appl Physiol,
May 1, 2002;
92(5):
1789 - 1794.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. Goodnough, D. J. Kuter, J. McCullough, S. J. Slichter, J. DiPersio, J. Romo, R. Peterson, K. J. Smith, T. Raife, D. Tomita, et al.
Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin
Blood,
September 1, 2001;
98(5):
1346 - 1351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Price, R. A. Bowden, M. Boeckh, J. Bux, K. Nelson, W. C. Liles, and D. C. Dale
Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation
Blood,
June 1, 2000;
95(11):
3302 - 3309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Adkins, L. T. Goodnough, S. Shenoy, R. Brown, J. Moellering, H. Khoury, R. Vij, and J. DiPersio
Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation
Blood,
June 1, 2000;
95(11):
3605 - 3612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Ringden, M. Remberger, V. Runde, M. Bornhauser, I.W. Blau, N. Basara, K. Holig, D.W. Beelen, H. Hagglund, O. Basu, et al.
Peripheral Blood Stem Cell Transplantation From Unrelated Donors: A Comparison With Marrow Transplantation
Blood,
July 15, 1999;
94(2):
455 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Engelhardt, H. Bertz, M. Afting, C. F. Waller, and J. Finke
High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ Immunoselection
J. Clin. Oncol.,
July 1, 1999;
17(7):
2160 - 2160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Skold, B. Rosberg, U. Gullberg, and T. Olofsson
A Secreted Proform of Neutrophil Proteinase 3 Regulates the Proliferation of Granulopoietic Progenitor Cells
Blood,
February 1, 1999;
93(3):
849 - 856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ozsahin, M. von Planta, I. Muller, H. C. Steinert, D. Nadal, R. Lauener, P. Tuchschmid, U. V. Willi, M. Ozsahin, N. E.A. Crompton, et al.
Successful Treatment of Invasive Aspergillosis in Chronic Granulomatous Disease by Bone Marrow Transplantation, Granulocyte Colony-Stimulating Factor-Mobilized Granulocytes, and Liposomal Amphotericin-B
Blood,
October 15, 1998;
92(8):
2719 - 2724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Beelen, H. D. Ottinger, A. Elmaagacli, B. Scheulen, O. Basu, B. Kremens, W. Havers, H. Grosse-Wilde, and U. W. Schaefer
Transplantation of Filgrastim-Mobilized Peripheral Blood Stem Cells From HLA-Identical Sibling or Alternative Family Donors in Patients With Hematologic Malignancies: A Prospective Comparison on Clinical Outcome, Immune Reconstitution, and Hematopoietic Chimerism
Blood,
December 15, 1997;
90(12):
4725 - 4735.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Anderlini, M. Korbling, D. Dale, A. Gratwohl, N. Schmitz, D. Stroncek, C. Howe, S. Leitman, M. Horowitz, E. Gluckman, et al.
Allogeneic Blood Stem Cell Transplantation: Considerations for Donors
Blood,
August 1, 1997;
90(3):
903 - 908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Urbano-Ispizua, C. Rozman, C. Martinez, P. Marin, J. Briones, M. Rovira, P. Feliz, M. Cruz Viguria, A. Merino, J. Sierra, et al.
Rapid Engraftment Without Significant Graft-Versus-Host Disease After Allogeneic Transplantation of CD34+ Selected Cells From Peripheral Blood
Blood,
June 1, 1997;
89(11):
3967 - 3973.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Korbling
Peripheral Blood Stem Cells: A Novel Source for Allogeneic Transplantation
Oncologist,
April 1, 1997;
2(2):
104 - 104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
